- Home
- LFT vs ATNM Comparison
LFT vs ATNM Comparison
Compare LFT & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFT | ATNM |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 31.4M |
| IPO Year | 2012 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LFT | ATNM |
|---|---|---|
| Price | $4.02 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 19.4K | ★ 227.7K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | ★ 29.63% | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | $168.78 | $38,788.89 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.99 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $3.85 | $0.74 |
| 52 Week High | $69.35 | $1.72 |
Technical Indicators
Market Signals| Indicator | LFT | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 43.92 | 56.77 |
| Support Level | N/A | $0.91 |
| Resistance Level | $5.83 | $1.44 |
| Average True Range (ATR) | 0.16 | 0.14 |
| MACD | 0.19 | 0.00 |
| Stochastic Oscillator | 23.33 | 59.02 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.